Survey of removing inhibitors in hemophilia A treatment
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male
- You have hemophilia A (a problem with clotting factor VIII)
- Your clotting factor VIII level is in a severe, moderate, or mild range
- You either have an inhibitor level above 0.6 BU, or—if below that—your body is not using factor well (reduced recovery or shorter half-life)
- You can be included even if you tried and did not succeed with inhibitor removal before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This study tests an experimental oral medication (Inno8) for people with hemophilia A. It aims to find the best dose and see how the body handles it. You may be able to join if you have mild to severe hemophilia A and are not on other preventive treatments.
This study looks at different ways to help blood clot in people with hemophilia who have developed inhibitors (proteins that stop standard clotting treatments from working). It may help doctors choose the safest, most effective clotting approach for these situations.
This study looks at how often people with hemophilia A develop inhibitors (antibodies that block the effectiveness of factor VIII) after using Coageight, a factor VIII replacement therapy. It may help understand the safety of this treatment.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This trial tests a new drug called KN057 for people with severe hemophilia A or moderate-to-severe hemophilia B, whether or not they have developed inhibitors (antibodies that block standard treatments). The goal is to see if it can help prevent or treat bleeding episodes.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.